Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy

Open access
Agewall, Stefan, Cattaneo, M., Collet, J.P., Andreotti, F., Lip, G.Y.H., Verheugt, F.W.A., Huber, K., Grove, E.L., Morais, J., Husted, S., Wassmann, S., Rosano, G., Atar, D., Pathak, A., Kjeldsen, K., Storey, R.F., on behalf of ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis · 2013 · European Heart Journal

Abstract

The ESC NSTEMI and STEMI guidelines1,2 and an ACCF/ACG/AHA consensus document3 recommend treatment with proton pump inhibitors (PPIs) in patients treated with dual antiplatelet treatment (DAPT) during the initial phase of an acute coronary syndrome (ACS) (ESC Class 1A recommendation), particularly in patients with a history of GI bleeding or peptic ulcer. Several studies have raised concerns that many PPIs, especially omeprazole, might diminish the antiplatelet effects of clopidogrel, most likely through inhibition of CYP2C19 and, consequently, the conversion of clopidogrel into its active metabolite.4,5 The aim of this position paper is to review the pharmacokinetic background of the interactions between these drugs, and their consequences on clinical outcomes, and to present suggestions for management of this important issue. Several agents widely used in patients on acetylsalicylic acid (ASA) may interact with the antiplatelet effects of ASA, but none through the CYP2C9 pathway by which ASA is metabolized. Recently, it has been reported that concomitant use of PPIs reduces the protective efficacy of ASA in patients with ischaemic heart disease.6,7 A case–control study investigated the antiplatelet effect of ASA in 418 ASA-treated CVD patients, 54 of whom were also treated with PPIs.7 Patients receiving PPIs had reduced antiplatelet effect of ASA, as shown by greater residual platelet aggregation responses. However, interaction between PPI and ASA is controversial.8 Potential clinical implications of these findings were explored by a registry study in a large population of ASA-treated patients with first time myocardial infarction.6 Even after adjusting for baseline variables with multivariate analysis and propensity score matching, PPI use was still significantly associated with ∼50% more ischaemic cardiovascular events. A sensitivity analysis showed no increase in risk related to the use of H2 receptor blockers.6 Suggested explanations for the observed interaction of PPIs with ASA in cardiovascular patients are (i) the reduced gastric acidity inhibiting the uptake of the weakly acidic ASA, (ii) the worse baseline characteristics of patients with concomitant GI disorders, and (iii) the play of chance. The studies on ASA uptake in relation to gastric acidity show negative findings.8,9 Even with multivariate and propensity score matching analyses, the existence of unrecognized confounding variables can never be excluded in the absence of randomized controlled trials. So far, there are insufficient data to suggest a clinical interaction between PPI use and the protective efficacy of ASA in patients with CVD. Use of PPIs is recommended for the prevention of gastric ulceration in ASA-treated patients at high risk of GI bleeding. Clopidogrel is a pro-drug that is metabolized in a two-step oxidative process10 (Figure 1). In the first step, the CYP isozymes CYP1A2, CYP2B6, and CYP2C19 form 2-oxo-clopidogrel that is then oxidized to the clopidogrel active metabolite by CYP2B6, CYP2C19, and CYP3A4. CYP2C19 contributes to 40% of the hepatic conversion of clopidogrel into the short half-life active metabolite that irreversibly binds to the platelet P2Y12 receptor.11 Two-step metabolic activation of clopidogrel. Bioavailability of the pro-drug is determined by intestinal absorption, which might be limited by the efflux pump MDR1 (encoded by ABCB1). Subsequently, 85% of the pro-drug is converted into inactive metabolites by ubiquitous esterases. The remaining 15% is converted into a thiol-containing active metabolite through two-step oxidations that involve several cytochrome P450 enzymes. The first oxidative step is catalysed by CYP2C19, CYP1A2 and CYP2B6 isoenzymes, producing the intermediate 2-oxo-clopidogrel. The second step is mediated by CYP3A4, CYP2B6, CYP2C19, and CYP2C9 and yield the bioactive metabolite, the cis-thiol isomer which irreversibly binds to platelet P2Y12 receptors inhibits ADP-induced platelet activation. The activity of CYP2C19 may be altered by xenobiotics such as PPIs, which are CYP2C19 substrates and interact with clopidogrel metabolism as a result of competitive antagonism. The interaction between PPIs and clopidogrel depends on the potency of each PPI to inhibit CYP2C19, ranging from stronger inhibitors such as lansoprazole (Ki: 0.4–1.5 μM), omeprazole (Ki: 2–6 μM), and esomeprazole (Ki: 8 μM) down to weaker ones such as rabeprazole (Ki: 17–21 μM) and pantoprazole (Ki: 14–69 μM).12 A PPI with less CYP2C19 inhibitory capacity (e.g. pantoprazole) may represent a more optimal treatment option than a PPI with high CYP2C19 inhibitory capacity (e.g. omeprazole) in patients who require both clopidogrel and a PPI (Figures 2 and 3).13 Pharmacodynamic interactions between proton pump inhibitors and clopidogrel: a metabolic drug–drug interaction exists between clopidogrel and omeprazole but not between clopidogrel and pantoprazole.37 The proton pump inhibitor treatment algorithm in patients with acut

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/eht042

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 202

Metadata

Authors
Agewall, S., Cattaneo, M., Collet, J. P., Andreotti, F., Lip, G. Y. H., Verheugt, F. W. A., Huber, K., Grove, E. L., Morais, J., Husted, S., Wassmann, S., Rosano, G., Atar, D., Pathak, A., Kjeldsen, K., Storey, R. F., & on behalf of ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis
Venue
European Heart Journal
Published
2013-02-20
Volume
34
Issue
23
Pages
1708-1713
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2096215047
Cited by
202
References
7
FWCI
13.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. https://app.cochat.ai/papers/10.1093/eurheartj/eht042
The paper
Agewall, S., Cattaneo, M., Collet, J. P., Andreotti, F., Lip, G. Y. H., Verheugt, F. W. A., Huber, K., Grove, E. L., Morais, J., Husted, S., Wassmann, S., Rosano, G., Atar, D., Pathak, A., Kjeldsen, K., Storey, R. F., & on behalf of ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. (2013). Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. European Heart Journal. https://doi.org/10.1093/eurheartj/eht042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.